-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] In the pharmaceutical market, nervous system drugs have always been one of the largest areas
.
It is understood that in the sub-category pattern, there are 7 sub-categories of nervous system drugs, including psychostimulants, pain relievers, anesthetics, tranquilizers, and antiepileptic drugs
.
Among them, the analgesic market is the fastest growing drug market among the five sub-categories of nervous system drugs that exceed 10 billion yuan
.
According to data, in 2019, the market size of terminal analgesics in China's public medical institutions is close to 18.
4 billion.
With the aging of the population, the incidence and operation rates of various major diseases continue to increase, coupled with various new treatment technologies.
Due to the continuous application in clinical practice, the rigid demand for surgical treatment in China is still rapidly expanding and other reasons, the analgesic market is still accelerating its growth
.
In this context, more and more domestic pharmaceutical companies have begun to increase their investment in this field, and the research and development of related drugs is also accelerating
.
Recently, Renfu Pharma announced that the clinical application for the Class 1 new drug RFUS-144 injection of its holding subsidiary Yichang Renfu was accepted by CDE
.
The drug is a selective opioid receptor agonist.
Data show that in 2020, the sales of terminal opioid painkillers in Chinese public medical institutions exceeded 12.
6 billion yuan
.
Renfu Medicine is a national designated R&D and production enterprise for narcotic drugs, and has certain advantages in the domestic anesthesia and analgesia field
.
RFUS-144 injection is Renfu Medicine's first Class 1 new drug to apply for clinical application this year.
In addition to Class 1 new drugs, Renfu Medicine has also made a series of progress in the field of improved new drugs this year, including the application for isoflurane injection.
3 new drugs, including acetaminophen and oxycodone sustained-release tablets, dexmedetomidine hydrochloride nasal spray, and dexmedetomidine transdermal patch (II), were approved for clinical use
.
On February 10, Kangfang Bio announced that the clinical trial application for the innovative nerve growth factor (NGF) monoclonal antibody injection independently developed by the company has been approved by the Center for Drug Evaluation (CDE) of the State Drug Administration.
Treat pain (including cancer pain)
.
The research and development of NGF monoclonal antibody is the first time for Kangfang Bio to enter the field of pain
.
Compared with traditional opioid painkillers, the drug has the advantages of long-term safety and non-addiction
.
In January, the website of the State Food and Drug Administration showed that the ropivacaine hydrochloride injection of Yangzijiang Pharmaceutical Group Nanjing Hailing Pharmaceuticals entered the administrative approval stage
.
Ropivacaine is a pure L-body long-acting amide local anesthetic with dual effects of anesthesia and analgesia.
Large doses can produce surgical anesthesia, while small doses produce sensory block (analgesia) with only limited non-progressive effects.
Motor block for surgical anesthesia and acute pain control
.
It is understood that in 2020, the sales of terminal ropivacaine hydrochloride injection in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will exceed 700 million yuan, and the first half of 2021 will increase year-on-year.
27.
22%
.
At present, China's painkiller industry is in the growth stage of the industry, the industry demand is strong, and the industry chain structure is complete
.
The industry expects that with the launch of more varieties in the future, the competition in the painkiller market may become more intense
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
It is understood that in the sub-category pattern, there are 7 sub-categories of nervous system drugs, including psychostimulants, pain relievers, anesthetics, tranquilizers, and antiepileptic drugs
.
Among them, the analgesic market is the fastest growing drug market among the five sub-categories of nervous system drugs that exceed 10 billion yuan
.
According to data, in 2019, the market size of terminal analgesics in China's public medical institutions is close to 18.
4 billion.
With the aging of the population, the incidence and operation rates of various major diseases continue to increase, coupled with various new treatment technologies.
Due to the continuous application in clinical practice, the rigid demand for surgical treatment in China is still rapidly expanding and other reasons, the analgesic market is still accelerating its growth
.
In this context, more and more domestic pharmaceutical companies have begun to increase their investment in this field, and the research and development of related drugs is also accelerating
.
Recently, Renfu Pharma announced that the clinical application for the Class 1 new drug RFUS-144 injection of its holding subsidiary Yichang Renfu was accepted by CDE
.
The drug is a selective opioid receptor agonist.
Data show that in 2020, the sales of terminal opioid painkillers in Chinese public medical institutions exceeded 12.
6 billion yuan
.
Renfu Medicine is a national designated R&D and production enterprise for narcotic drugs, and has certain advantages in the domestic anesthesia and analgesia field
.
RFUS-144 injection is Renfu Medicine's first Class 1 new drug to apply for clinical application this year.
In addition to Class 1 new drugs, Renfu Medicine has also made a series of progress in the field of improved new drugs this year, including the application for isoflurane injection.
3 new drugs, including acetaminophen and oxycodone sustained-release tablets, dexmedetomidine hydrochloride nasal spray, and dexmedetomidine transdermal patch (II), were approved for clinical use
.
On February 10, Kangfang Bio announced that the clinical trial application for the innovative nerve growth factor (NGF) monoclonal antibody injection independently developed by the company has been approved by the Center for Drug Evaluation (CDE) of the State Drug Administration.
Treat pain (including cancer pain)
.
The research and development of NGF monoclonal antibody is the first time for Kangfang Bio to enter the field of pain
.
Compared with traditional opioid painkillers, the drug has the advantages of long-term safety and non-addiction
.
In January, the website of the State Food and Drug Administration showed that the ropivacaine hydrochloride injection of Yangzijiang Pharmaceutical Group Nanjing Hailing Pharmaceuticals entered the administrative approval stage
.
Ropivacaine is a pure L-body long-acting amide local anesthetic with dual effects of anesthesia and analgesia.
Large doses can produce surgical anesthesia, while small doses produce sensory block (analgesia) with only limited non-progressive effects.
Motor block for surgical anesthesia and acute pain control
.
It is understood that in 2020, the sales of terminal ropivacaine hydrochloride injection in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will exceed 700 million yuan, and the first half of 2021 will increase year-on-year.
27.
22%
.
At present, China's painkiller industry is in the growth stage of the industry, the industry demand is strong, and the industry chain structure is complete
.
The industry expects that with the launch of more varieties in the future, the competition in the painkiller market may become more intense
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
